 Home > Biochemistry News > Biotechnology News > The U.S. Food and Drug Administration (FDA) approves Opdivo(R) (nivolumab) in combination with chemotherapy for the neoadjuvant treatment of selected adult patients with resectable non-small cell lung cancer

The U.S. Food and Drug Administration (FDA) approves Opdivo(R) (nivolumab) in combination with chemotherapy for the neoadjuvant treatment of selected adult patients with resectable non-small cell lung cancer

 Last Update: 2022-05-23
 Source: Internet
 Author: User

Tags

estazolam 2 mg

1 3 bisphosphoglycerate

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

SHANGHAI, March 6, 2022 /PRNewswire/ -- On March 4, 2022, Bristol-Myers Squibb (announced that the U.

In this clinical trial, preoperative use of nivolumab in combination with chemotherapy demonstrated a statistically significant improvement in event-free survival (EFS) compared with chemotherapy alone37 % (HR 0.

"Considering that a large proportion of patients with resectable non-small cell lung cancer will have a postoperative recurrence occurs, so preoperative treatment is expected to help patients improve their chances of success with surgery while reducing the risk of cancer recurrence

Nivolumab involves the following warnings and precautions: Serious and fatal immune-mediated adverse reactions, including pneumonitis, colitis, hepatitis or hepatotoxicity, endocrinopathy, cutaneous adverse reactions, nephritis with renal insufficiency, and other immune-mediated adverse reactions adverse reactions; infusion-related reactions; complications of allogeneic hematopoietic stem cell transplantation (HSCT); embryo-fetal toxicity; Mortality is increased, so use outside of controlled clinical trials is not recommended

Adam Lenkowsky, senior vice president and general manager of Bristol-Myers Squibb's U.

The application was approved under the FDA's Real-Time Oncology Review (RTOR) pilot program, which is designed to ensure safe and effective treatment for patients as early as possible

(This indication has not yet been approved in China

About CheckMate -816

CheckMate -816 is a global randomized, open-label Phase III clinical study to evaluate the neoadjuvant treatment of nivolumab in combination with platinum-based doublet chemotherapy compared with chemotherapy alone in adult patients with resectable non-small cell lung cancer efficacy, regardless of PD-L1 expression levels

The primary endpoints of the study were event-free survival as determined by blinded independent central review (BICR) and pathological complete response rate as determined by blinded independent pathological review (BIPR)

About Lung Cancer

Lung cancer is the leading cause of cancer death worldwide

Source: Bristol-Myers Squibb

The original is abridged

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.